Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments

Bibliography

• HUGGINS C, STEVENS RE Jr, HODGES CV: Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. (1941) 43:209-223.
   Google Scholar
• HUGGINS C, HODGES CV: Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. (1941) 1:293-297.
   Google Scholar
• LIN BJ, CHEN KK, CHEN MT, CHANG LS: The time for serumtestosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology (1994) 43(6):834-837.
   PubMed Web of Science ®Google Scholar
• BYAR DP, CORLE DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. (1988) (7):165-170.
   PubMedGoogle Scholar
• SCHALLY AV, KASTIN AJ, ARIMURA A: Hypothalamic FSH and LH regulating hormone. Structure, physiology and clinical studies. Fertil. Steril. (1971) 22:703-721.
   PubMed Web of Science ®Google Scholar
• TOMBAL B, BERGES R: How good do current LHRH agonists control testosterone? Can this be improved with eligard? Eur. Urol. Suppl. (2005) 4:30-36.
   Google Scholar
• KAWAKAMI J, MORALES A: A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J. Urol. (2002) 167:288 (Abstract 1135).
   PubMedGoogle Scholar
• OEFELEIN MG, CORNUM R: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J. Urol. (2000) 164(3 Pt 1):726-729.
   PubMedGoogle Scholar
• SHARIFI N, GULLEY JL, DAHUT WL: Androgen deprivation therapy for prostate cancer. JAMA (2005) 294:238-244.
   PubMed Web of Science ®Google Scholar
• MESSING EM, MANOLA J, SAROSDY M et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. (1999) 341:1781-1788.
   PubMed Web of Science ®Google Scholar
• MESSING E, MANOLA J, SAROSDY et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J. Urol. (2003) 169:396.
   Google Scholar
• MEDICAL RESEARCH COUNCIL PROSTATE CANCER WORKING PARTY INVESTIGATORS GROUP: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br. J. Urol. (1997) 79:235-246.
   PubMedGoogle Scholar
• PROSTATE CANCER TRIALISTS’ COLLABORATIVE GROUP: Maximum androgen blockade in advanced prostate cancer. an overview of the randomised trials. Lancet (2000) 355:1491-1498.
   PubMed Web of Science ®Google Scholar
• BERTAGNA C, DE GÉRY A, HUCHER M, FRANÇOIS JP, ZANIRATO J: Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br. J. Urol. (1994) 73:396-402.
   PubMedGoogle Scholar
• CAUBET J-F, TOSTESON TD, DONG EW et al.: Maximum androgen blockade in advanced prostate cancer. A metaanalysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology (1997) 49:71-78.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, TOSTESON TD, SCHMITT B et al.: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer. A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prost. Dis. (1999) 2:4-8.
   PubMed Web of Science ®Google Scholar
• KLOTZ L: Combined androgen blockade in prostate cancer. Meta-analyses and associated issues. BJU Int. (2001) 87:806-813.
   PubMed Web of Science ®Google Scholar
• CRAWFORD ED, EISENBERGER MA, MCLEOD DG et al.: Controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. (1989)321 (7) :419-424.
   PubMed Web of Science ®Google Scholar
• EISENBERGER MA, BLUMENSTEIN BA, CRAWFORD ED et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. (1998) 339:1036-1042.
   PubMed Web of Science ®Google Scholar
• STUDER UE, HAURI D, HANSELMANN S et al.: Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J. Clin. Oncol. (2004) 22:4109-4118.
   PubMed Web of Science ®Google Scholar
• STUDER UE, WHELAN P, ALBRECHT W et al.: Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J. Clin. Oncol. (2006) 24(12):1868-1876.
   PubMedGoogle Scholar
• INITIAL RESULTS OF THE MEDICAL RESEARCH COUNCIL TRIAL: Immediate versus deferred treatments for advanced prostatic cancer. Br. J. Urol. (1997) 79:235-246.
   PubMedGoogle Scholar
• MOUL JW, HARDING P, CRAWFORD ED, MCLEOD DG: Combination flutamide and finasteride in PSA-only recurrence after prior local prostate cancer therapy. J. Urol. (1998) 159(Suppl.):130.
   Google Scholar
• PROSTATE CANCER TRIALISTS’ COLLABORATIVE GROUP: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet (2000) 355:1491-1498.
   PubMed Web of Science ®Google Scholar
• LOBLAW DA, MENDELSON DS, TALCOTT JA et al.: American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J. Clin. Oncol. (2004) 22:2927-2941.
   PubMed Web of Science ®Google Scholar
• GROSSFELD GD, SMALL EJ, LUBECK DP, LATINI D, BROERING JM, CARROLL PR: Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology (2001) 58(2 Suppl. 1):56-64.
   PubMedGoogle Scholar
• SEIDENFELD J, SAMSON DJ, HASSELBLAD V et al.: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. (2000) 32(7):566-577.
   Google Scholar
• IVERSEN P, TYRRELL CJ, KAISARY AV et al.: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology (1998) 51(3):389-396.
   PubMed Web of Science ®Google Scholar
• WIRTH M, TYRRELL C, DELAERE K et al.: ‘Casodex’ Early Prostate Cancer Trialists’ Group. Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind Phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis. (2005) 8(2):194-200.
   PubMedGoogle Scholar
• IVERSEN P, TYRRELL CJ, KAISARY AV et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer. 6.3 years of followup. J. Urol. (2000) 164:1579-1582.
   PubMed Web of Science ®Google Scholar
• TYRRELL CJ, KAISARY AV, IVERSEN P et al.: A randomised comparison of ‘Casodex’™ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. (1998) 33:447-456.
   PubMed Web of Science ®Google Scholar
• BOHL CE, GAO W, MILLER DD, BELL CE, DALTON JT: Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci USA (2005) 102(17):6201-6206.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, AKAKURA K, KOMIYA A, AIDA S, AKIMOTO S, SHIMAZAKI J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate (1996) 29:153-158.
   PubMed Web of Science ®Google Scholar
• HARA T, MIYAZAKI J, ARAKI H et al.: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. (2003) 63:149-153.
   PubMed Web of Science ®Google Scholar
• YIN D, HE Y, PERERA MA et al.: Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. (2003) 63(1):211-223.
   PubMed Web of Science ®Google Scholar
• CHEN J, HWANG DJ, BOHL CE, MILLER DD, DALTON JT: A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. (2005) 312:546-553.
   PubMed Web of Science ®Google Scholar
• GAO W, KEARBEY JD, NAIR VA et al.: Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology (2004) 145:5420-5428.
   PubMed Web of Science ®Google Scholar
• SHARIFI R, BROWNELLER R: Leuprolide Study Group. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J. Urol. (2002) 168(3):1001-1004.
   PubMed Web of Science ®Google Scholar
• OEFELEIN MG, FENG A, SCOLIERI MJ, RICCHIUTTI D, RESNICK MI: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology (2000) 56(6):1021-1024.
   PubMed Web of Science ®Google Scholar
• ZLOTTA AR, DEBRUYNE FMJ: Expert opinion on optimal testosterone control in prostate cancer. Eur. Urol. Suppl. (2005) 4:37-41.
   Web of Science ®Google Scholar
• ROHL HF, BEUKE HP: Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand. J. Urol. Nephrol. (1992) 26(1):11-14.
   PubMed Web of Science ®Google Scholar
• ESQUENA S, ABASCAL JM, TRILLA E, MOROTE J: Failure of luteinisinghormonal releasing hormonal agonist therapy to achieve castration. Does it exist? Eur. Urol. Suppl. (2004) 3:57.
   Google Scholar
• OEFELEIN MG, CORNUM R: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J. Urol. (2000) 164(3 Pt 1):726-729.
   PubMedGoogle Scholar
• WECHSEL HW, ZERBIB M, PAGANO F, COPTCOAT MJ: Randomized open labelled comparative study of the efficacy, safety and tolerability of euprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur. Urol. (1996) 30(Suppl. 1):7-14.
   PubMedGoogle Scholar
• MCLEOD D, ZINNER N, TOMERA K et al.: Abarelix Study Group. A Phase III, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology (2001) 58(5):756-761.
   PubMed Web of Science ®Google Scholar
• SAROSDY MF, SCHELLHAMMER PF, SOLOWAY MS et al.: Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every13 weeks to patients with advanced prostate cancer. Br. J. Urol. Int. (1999) 83:801-806.
   Google Scholar
• ZINNER N, BIDAIR M, CENTENO A, TOMERA K: Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology (2004) 64:1177-1181.
   PubMed Web of Science ®Google Scholar
• JOCHAM D: Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol. Int. (1998) 60(Suppl. 2):18-24.
   PubMedGoogle Scholar
• TOMBAL B: Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur. Urol. Suppl. (2005) 4:14-19.
   Web of Science ®Google Scholar
• MARKS LS: Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology (2003) 62:36-42.
   PubMed Web of Science ®Google Scholar
• CHU FM, JAYSON M, DINEEN MK, PEREZ R, HARKAWAY R, TYLER RC: A clinical study of 22.5 mg LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J. Urol. (2002) 168:1199-1203.
   PubMed Web of Science ®Google Scholar
• PEREZ-MARRENO R, CHU FM, GLEASON D, LOIZIDES E, WACHS B, TYLER RC: A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin. Ther. (2002) 24:1902-1914.
   PubMed Web of Science ®Google Scholar
• PEREZ-MARRENO R, TYLER RC: A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert. Opin. Pharmacother. (2004) 5:447-457.
   PubMedGoogle Scholar
• WECKERMANN D, HARZMANN R: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur. Urol. (2004) 46:279-284.
   PubMed Web of Science ®Google Scholar
• TOMERA K, GLEASON D, GITTLEMAN M et al.: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J. Urol. (2001) 165:1585-1589.
   PubMed Web of Science ®Google Scholar
• TRACHTENBERG J, GITTLEMAN M, STEIDLE C et al.: A Phase III, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. (2002) 167:1670-1674.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, HALABI S, DAWSON NA et al.: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a Phase III trial (CALGB 9583). J. Clin Oncol. (2004) 22:1025-1033.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, DE WIT R, BERRY WR et al. FOR THE TAX 327 INVESTIGATORS: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. (2004) 351:1502-1512.
   PubMed Web of Science ®Google Scholar
• PETRYLAK DP, TANGEN CM, HUSSAIN MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. (2004) 351:1513-1520.
   PubMed Web of Science ®Google Scholar
• HUSSAIN A, DAWSON N, AMIN P et al.: Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J. Clin. Oncol. (2005) 23:2789-2796.
   PubMedGoogle Scholar
• EIGL BJC, EGGENER SE, BAYBIK J et al.: Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin. Cancer. Res. (2005) 11(13):4905-4911.
   PubMedGoogle Scholar
• FEBBO PG, RICHIE JP, GEORGE DJ et al.: Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer. Res. (2005) 11(14):5233-5240.
   PubMed Web of Science ®Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411-415.
   PubMed Web of Science ®Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA (1989) 86:2863-2867.
   PubMed Web of Science ®Google Scholar
• PRAYER-GALETTI T, ROSSI GP, BELLONI AS et al.: Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate. J. Urol. (1997) 157:2334-2339.
   PubMed Web of Science ®Google Scholar
• GOHJI K, KITAZAWA S, TAMADA H, KATSUOKA Y, NAKAJIMA M: Expression of endothelin receptor a associated with prostate cancer progression. J. Urol. (2001) 165(3):1033-1036.
   PubMed Web of Science ®Google Scholar
• NELSON JB, NGUYEN SH, WU-WONG JR et al.: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology (1999) 53:1063-1069.
   PubMed Web of Science ®Google Scholar
• NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944-999.
   PubMed Web of Science ®Google Scholar
• PAPANDREOU CN, USMANI B, GENG Y et al.: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med. (1998) 4:50-57.
   PubMed Web of Science ®Google Scholar
• YIN JJ, MOHAMMAD KS, KAKONEN SM et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl Acad. Sci. USA (2003) 100:10954-10959.
   PubMed Web of Science ®Google Scholar
• CARDUCCI MA, PADLEY RJ, BREUL J et al.: Effect of endothelin- a receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, Phase II, placebo-controlled trial. J. Clin. Oncol. (2003) 21:679-689.
   PubMed Web of Science ®Google Scholar
• NELSON JB: Endothelin receptor antagonists. World J. Urol. (2005) 23:19-27.
   PubMed Web of Science ®Google Scholar
• O’MALLEY BW, SCHRADER WT, MANI S et al.: An alternative ligand-independent pathway for activation of steroid receptors. Recent Prog. Horm. Res. (1995) 50:333-347.
   PubMedGoogle Scholar
• CHANG C, ABDO J, HARTNEY T, MCDONNELL DP: Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Molec. Endocr. (2005) 19(10):2478-2490.
   PubMed Web of Science ®Google Scholar
• CHEN A, KAGANOVSKY E, RAHIMIPOUR S et al.: Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breast tissue and overexpressed in breast cancer: a putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2. Cancer Res. (2002) 62:1036-1044.
   PubMed Web of Science ®Google Scholar
• CHEN A, GANOR Y, RAHIMIPOUR S et al.: The neuropeptides GnRH-II and Gnrh-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat. Med. (2002) 8:1421-1426.
   PubMed Web of Science ®Google Scholar
• MARELLI MM, MORETTI RM, DONDI D, MOTTA M, LIMONTA P: Luteinizing hormone releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology (1999) 140:329-334.
   PubMed Web of Science ®Google Scholar
• MAITI K, OH DY, MOON JS et al.: Effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. J. Clin. Endocrinol. Metab. (2005) 90(7):4287-4298.
   PubMed Web of Science ®Google Scholar
• HURKADLI KS, SHETH AR, GARDE SV, DOCTOR VM, SHETH NA: Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates. Br. J. Cancer (1990) 61:225-229.
   PubMedGoogle Scholar
• BEN-JOSEF E, YANG SY, JI TH et al.: Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J. Urol. (1999) 161:970-976.
   PubMed Web of Science ®Google Scholar
• MAHLER C, VERHELST J, CHABAN M, DENIS L: Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormonereleasing hormone (LHRH) challenge in patients having longterm treatment with a depot LHRH analogue. Cancer (1991) 67:557-559.
   PubMed Web of Science ®Google Scholar
• BEER TM, GARZOTTO M, EILERS KM, LEMMON D, WERSINGER EM: Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology (2004) 63:342-347.
   PubMed Web of Science ®Google Scholar
• CHEN CD, WELSBIE DS, TRAN C et al.: Molecular determinants of resistance to antiandrogen therapy. Nat. Med. (2004) 10:33-39.
   PubMed Web of Science ®Google Scholar
• ALGARTÉ-GÉNIN M, CUSSENOT O, COSTA P: Experimental paradox or clinical reality. Eur. Urol. (2004) 46:285-295.
   PubMed Web of Science ®Google Scholar
• POUND CR, PARTIN AW, EISENBERGER MA, CHAN DW, PEARSON JD, WALSH PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 281(17):1591-1597.
   PubMed Web of Science ®Google Scholar
• PIENTA K, SMITH DC: Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J. Clin. (2005) 55:300-318
   PubMedGoogle Scholar
• SCHER HI, SAWYERS CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. (2005) 23:8253-8261.
   PubMed Web of Science ®Google Scholar
• BERGES R: Eligard®: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur. Urol. Suppl. (2005) 4:20-25.
   Google Scholar
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br. J. Urol. (1997) 79(2):235-246.
   Google Scholar
• BOLLA M, COLLETTE L, BLANK L et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 360(9327):103-106.
   Google Scholar
• BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. (1997) 337(5):295-300.
   Google Scholar
• PILEPICH MV, WINTER K, JOHN MJ et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50(5):1243-1252.
   Google Scholar
• D'AMICO AV, MANOLA J, LOFFREDO M, RENSHAW AA, DELLACROCE A, KANTOFF PW: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA (2004) 292(7):821-827.
   Google Scholar